Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AZN

NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History

NEW YORK, June 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on June 5thInvestors are reacting to the May jobs…

AAP

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

With after-tax profits surging by close to 50% year-over-year, AstraZeneca emerges as a potential winner among healthcare names reporting earnings this month.

MarketBeat

AstraZeneca's Hard To Control Hypertension Drug Advances, With FDA Decision Expected In 2026

On Tuesday, the U.S. Food and Drug Administration accepted AstraZeneca Plc's (NASDAQ:AZN) New Drug Application (NDA) for baxdrostat for adult patients with hard-to-control (uncontrolled or treatment-resistant) hypertension as an add-on to other antihypertensive medicines.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers

The U.S. Food and Drug Administration (FDA) on Tuesday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers.

Benzinga

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ:AZN), initially established in March 2025.

Benzinga

AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported third-quarter 2025 sales of $15.19 billion, up 12% year over year (+10% at constant currency), beating the consensus of $14.80 billion, driven by double-digit growth in oncology, CVRM, and biopharmaceuticals.

Benzinga

Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans

President Donald Trump is reportedly set to announce a new agreement with AstraZeneca Plc (NASDAQ:AZN) designed to reduce prescription drug costs for Americans.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity Drugs

AstraZeneca Plc (NASDAQ:AZN) on Thursday said it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500 million to support the enhanced manufacturing capability of a broader range of medicines, including cancer treatments.

Benzinga

AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension

On Tuesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Bax24 Phase 3 trial to evaluate the safety, tolerability, and the effect of 2mg baxdrostat versus placebo.

Benzinga

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases

Algen Biotechnologies, a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NASDAQ:AZN) to accelerate the discovery of novel therapeutic targets in immunology.

Benzinga

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy

AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo on Monday released high-level results from the TROPION-Breast02 Phase 3 trial.

Benzinga

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

Benzinga

AstraZeneca Moves From ADRs To NYSE Listing

The Board of AstraZeneca plc (NASDAQ: AZN) is recommending to shareholders a Harmonized Listing Structure for the company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE).

Benzinga

Your AstraZeneca Medicine Could Be Cheaper As Much As 70%

AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc.'s (NASDAQ:AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Benzinga

AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial

AstraZeneca Plc (NASDAQ:AZN) released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).

Benzinga

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.

Benzinga

FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer

On Wednesday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Koselugo (selumetinib) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), benign, nerve sheath tumors.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study

On Sunday, AstraZeneca Plc (AZN) released results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial in previously untreated patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletion or exon 21 L858R mutations.

Benzinga

AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure

On Saturday, AstraZeneca Plc (NASDAQ:AZN) released full results from the BaxHTN Phase 3 trial evaluating baxdrostat. The company released the topline data in July.

Benzinga

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.

Benzinga

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients.

Benzinga

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US

AstraZeneca plc (NASDAQ:AZN) announced on Tuesday that it will invest $50 billion in the United States by 2030.

Benzinga

AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy.

Benzinga

AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition

On Wednesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the London Stock Exchange

192 stories

Amgen

176 stories

the New York Stock Exchange

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.